Physician profile
Lori Davidson
NPI 1770583734
$53,708.94
in general payments reported to CMS, 2019-2025
53 companies · $2,334 in 2025
The $2,334 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,462 · 2020: $13K · 2021: $10K · 2022: $3,625 · 2023: $19K · 2024: $1,702 · 2025: $2,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $4,791 · Consulting Fee: $2,415 · Travel and Lodging: $534 · Education: $384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,000.00 |
| Food and Beverage | $4,790.56 |
| Consulting Fee | $2,415.00 |
| Travel and Lodging | $533.76 |
| Education | $383.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19,016.13 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $13,564.02 | 2019-2021 | |
| Abbvie INC. | $9,551.86 | 2019-2025 | Vraylar, Qulipta, Lo Loestrin Fe |
| Myovant Sciences INC. | $1,853.03 | 2021-2022 | |
| Duchesnay USA Incorporated | $1,676.26 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $1,216.27 | 2021 | |
| Novo Nordisk INC | $859.19 | 2019-2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $694.48 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $685.87 | 2019-2025 | Evenity, Prolia |
| Mayne Pharma Commercial LLC | $522.74 | 2021-2025 | |
| Radius Health, INC. | $378.84 | 2019-2025 | Tymlos |
| Therapeuticsmd, INC. | $374.54 | 2019-2022 | |
| Biofire Diagnostics, LLC | $300.00 | 2019 | |
| Bausch Health US, LLC | $276.96 | 2019-2023 | Wellbutrin, Aplenzin |
| Sumitomo Pharma America, INC. | $266.14 | 2023-2025 | Myfembree, Gemtesa |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Davidson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.